Apr 27, 2021
AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

Apr 07, 2021
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases

Mar 31, 2021
AIM ImmunoTech Reports 2020 Year-End Financial Results

Mar 22, 2021
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center's Ongoing Study in Cancer Patients with COVID-19

Mar 11, 2021
AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th

Mar 10, 2021
AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Mar 08, 2021
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study

Mar 04, 2021
AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th

Feb 24, 2021
AIM ImmunoTech's Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer

Feb 16, 2021
AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

 1   2   3   4   5     6    7   8   9   10   11